# Optimization of Antiviral Therapy of Chronic HBV Infection

> **NCT01623778** · — · COMPLETED · sponsor: **Changhai Hospital** · enrollment: 67 (actual)

## Conditions studied

- Australia Antigen Positive
- Hepatitis B
- Adverse Effects

## Interventions

- **DRUG:** Interferon Alfa-2a add on ADV

## Key facts

- **NCT ID:** NCT01623778
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2012-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623778, "Optimization of Antiviral Therapy of Chronic HBV Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01623778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*